SCHEMBL2633332

SCHEMBL2633332

CC(C)CC(NC(=O)[C@H](CCc1ccccc1)NC(=O)Nc1ccc(Cl)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 16/20 0.72
PSMB2 P49721 12/20 0.72
PSMB1 P20618 11/20 0.72
PSMB8 P28062 11/20 0.72
PSMB10 P40306 11/20 0.72
PSMB11 A5LHX3 10/20 0.72
PSMA7 O14818 10/20 0.72
PSMA1 P25786 10/20 0.72
PSMA2 P25787 10/20 0.72
PSMA3 P25788 10/20 0.72
PSMA4 P25789 10/20 0.72
PSMB9 P28065 10/20 0.72
PSMA5 P28066 10/20 0.72
PSMB4 P28070 10/20 0.72
PSMB6 P28072 10/20 0.72
PSMB3 P49720 10/20 0.72
PSMA6 P60900 10/20 0.72
PSMA8 Q8TAA3 10/20 0.72
PSMB7 Q99436 10/20 0.72
PSMD11 O00231 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18871668 1.00 PSMB5 (0.72) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL84962 0.94 PSMB5 (0.69) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL2633227 0.94 PSMB5 (0.69) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL18871669 0.93 PSMB5 (0.68) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL2633220 0.93 PSMB5 (0.68) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL2633334 0.93 PSMB5 (0.68) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL8282512 0.92 PSMB5 (0.70) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL18871924 0.92 PSMB5 (0.70) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL85003 0.90 PSMB5 (0.58) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL2632873 0.89 PSMB5 (0.68) PSMB5PSMB2PSMB1PSMB8PSMB10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170136085-A1 TARGETED THERAPEUTICS TVA (ABC), LLC 2017-05-18 US disclosed
US-20120094928-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2012-04-19 US disclosed
WO-2005105827-A2 COMPOUNDS FOR PROTEASOME ENZYME INHIBITION PROTEOLIX, INC. (US) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170136085-A1 TARGETED THERAPEUTICS HSP90B1, HSP90AB1, CDC37 PSMB5 1248/4885PSMB2 1729/4885PSMB1 1251/4885
US-20120094928-A1 COMPOUNDS FOR ENZYME INHIBITION ANPEP, DNPEP, CPN1 PSMB5 24/4885PSMB2 14/4885PSMB1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.